Global Parkinsons Disease (PD) Drugs Market Research Report 2019 (Includes Business Impact of COVID-19)

                                          
"The ongoing Coronavirus (COVID-19) pandemic is re-shaping everything from global economies to product categories, pricing, and stock availability to the consumer behavior. The final report is updated to address the impact of COVID-19 on the Parkinsons Disease (PD) Drugs market.

Trusted Business Insights is tracking mining/oil and gas, transportation, employment services, travel arrangements, and the leisure and hospitality sector closely as they are likely to be the hardest-hit sectors. Utilities, local pharma, diagnostics, consumer goods and durables, agro chem and fertilizers, and telecommunications are the sectors that will be weathering the COVID-19 storm and most likely come out relatively unscathed. Interdependencies of sectors are factored in our research report on the Parkinsons Disease (PD) Drugs market."
Parkinsons disease (PD) is a progressive neurodegenerative disorder characterized by damage to the dopaminergic neurons located in various parts of the brain, including the substantia nigra.
The emergence of gene therapy to reverse the progression of PD is one of the key trends that will gain traction in the market for parkinsons drugs throughout the estimated period.

The global Parkinsons Disease (PD) Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Parkinsons Disease (PD) Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Parkinsons Disease (PD) Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:
    Boehringer Ingelheim
    GlaxoSmithKline
    Novartis
    Teva Pharmaceutical Industries
    AbbVie
    Abital Pharma
    Addex Therapeutics
    Biogen
    Eisai
    Eli Lilly
    F. Hoffmann-La Roche
    H. Lundbeck
    Impax Laboratories
    Kyowa Hakko Kirin
    Otsuka Pharmaceutical
    Pfizer

Segment by Regions
    North America
    Europe
    China
    Japan

Segment by Type
    Dopamine Agonist
    Monoamine Oxidase Inhibitors
    Acetylcholinesterase Inhibitors
    Glutamate Inhibitors

Segment by Application
    Hospital
    Family